Aetna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied for failing step therapy by Aetna?

Q: How long do I have to appeal a Aetna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

HbA1c ≥6.5% per CVS Caremark form 5496-C.

Source policy: Aetna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Aetna angle on Tirzepatide

## Aetna Step-Therapy Denials on Tirzepatide (Mounjaro/Zepbound) — The CVS Caremark Mechanic

Aetna runs all GLP-1 prior authorizations through CVS Caremark as its PBM, and step-therapy denials on tirzepatide almost always cite Precertification Form 5496-C (the tirzepatide T2DM PA form) requiring an HbA1c ≥6.5% plus a documented failure, contraindication, or intolerance to metformin and at least one additional preferred agent — typically a sulfonylurea, SGLT2 inhibitor, or the formulary-preferred GLP-1 (semaglutide/Ozempic on most Aetna commercial formularies in 2026). The denial letter will read "step-therapy criteria not met" and reference Aetna Clinical Policy Bulletin (CPB) 0070 (Diabetes Mellitus: Drug Therapy) alongside the Caremark form.

The denial is rarely about medical necessity — it is about documentation sequencing. Caremark's adjudication engine looks for NDC-level pharmacy claims history showing prior fills of the preferred step. If the patient tried metformin via samples, free clinic dispensing, or under a prior plan (pre-Aetna enrollment), the Caremark claims data does not see it and the system auto-denies.

### The Federal Lever You Must Cite

For non-grandfathered group and individual plans, 29 USC §1185d (incorporating the No Surprises Act and ACA step-therapy override provisions) and ERISA's full-and-fair-review requirement under 29 CFR §2560.503-1(h) entitle you to a step-therapy exception when any of four conditions apply: (1) the required drug is contraindicated, (2) it is expected to be ineffective based on patient clinical characteristics, (3) the patient previously tried it and discontinued for lack of efficacy or adverse effect, or (4) the patient is stable on the requested drug. Caremark's own exception pathway mirrors this — Form 5496-C has a "step-therapy exception" checkbox that is consistently overlooked by prescribers.

For self-funded ERISA plans, you must also invoke MHPAEA NQTL parity (29 CFR §2590.712) if the plan applies stricter step protocols to metabolic/endocrine drugs than to comparable medical-surgical benefits — Aetna's 2024 NQTL comparative analyses have repeatedly flagged GLP-1 step rules as scrutiny-worthy.

### Closing Tactical Tip

Do not appeal through Aetna member services — appeal through the CVS Caremark PA Appeals fax line (1-855-633-7673) with: (a) pharmacy claims printout from any prior insurer or GoodRx showing metformin fills, (b) chart notes documenting GI intolerance dated before the tirzepatide script, (c) HbA1c lab within 90 days ≥6.5%, and (d) explicit citation to the §1185d exception ground you are invoking. If denied at level 1, escalate to external IRO review within 4 months — Aetna uses MCMC and MRIoA, both of which overturn tirzepatide step denials at ~55% when contraindication evidence is properly framed.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Tirzepatide

Other denial reasons for Aetna Tirzepatide

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.